Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
0.00 | 0.00 | 0.00 | 0.00 | 1.18M | Gross Profit |
0.00 | -836.00K | -1.47M | -736.00K | 107.00K | EBIT |
-142.47M | -170.28M | -127.44M | -83.56M | -43.66M | EBITDA |
-132.25M | -158.40M | -121.95M | -83.47M | -43.46M | Net Income Common Stockholders |
-134.85M | -160.81M | -123.48M | -83.46M | -45.74M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
127.76M | 182.74M | 282.91M | 363.67M | 434.22M | Total Assets |
147.78M | 242.55M | 306.49M | 380.18M | 436.05M | Total Debt |
435.00K | 17.20M | 10.43M | 742.00K | 0.00 | Net Debt |
-17.13M | -5.21M | -272.48M | -362.93M | -434.22M | Total Liabilities |
34.16M | 52.84M | 43.02M | 17.13M | 436.05M | Stockholders Equity |
113.62M | 189.71M | -325.47M | -201.99M | -118.52M |
Cash Flow | Free Cash Flow | |||
-122.36M | -131.64M | -90.65M | -73.02M | -38.32M | Operating Cash Flow |
-121.91M | -130.36M | -89.22M | -68.10M | -38.29M | Investing Cash Flow |
86.26M | 44.66M | -235.42M | -4.92M | 610.00K | Financing Cash Flow |
30.82M | 59.29M | 9.86M | 2.47M | 462.88M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
57 Neutral | $233.33M | ― | -270.01% | ― | -65.96% | 40.80% | |
52 Neutral | $5.28B | 3.75 | -42.72% | 2.86% | 17.70% | 2.03% | |
43 Neutral | $20.38M | ― | -56.54% | ― | 18.16% | 86.65% | |
41 Neutral | $28.53M | ― | -1038.73% | ― | ― | 34.97% | |
39 Underperform | $27.54M | ― | -88.91% | ― | ― | 30.37% | |
39 Underperform | $26.43M | ― | -1738.36% | ― | -47.71% | -244.00% | |
38 Underperform | $29.49M | ― | -91.02% | ― | 236.92% | -0.57% |
On February 28, 2025, ALX Oncology Holdings Inc. announced a 30% reduction in its workforce as part of a strategy to prioritize its pipeline, focus on clinical development, and preserve cash. This reduction, expected to be completed by May 2025, will incur estimated expenses of $2.2 million primarily related to research and preclinical development. Additionally, the company’s President and Chief Scientific Officer, Jaume Pons, Ph.D., will depart in April 2025 as a result of this workforce reduction. Dr. Pons will receive severance benefits and will enter a consulting agreement to assist with the transition.